Loading…
Wednesday, June 26 • 4:15pm - 5:30pm
#385: The Importance of Human Translation for Successful Preclinical Drug Discovery and Cardiac Safety

Sign up or log in to save this to your schedule and see who's attending!

Component Type: Session
Level: Advanced
CE: ACPE 1.25 Knowledge UAN: 0286-0000-19-704-L04-P; CME 1.25; IACET 1.25; RN 1.25

This session will discuss how human-focused translational technologies help ensure the safety and efficacy of novel therapies, reduce product development costs, shorten time to market and provide an unprecedented opportunity to unlock new possibilities for preclinical drug discovery.

Learning Objectives

Discuss the importance of human cells and/or tissue in early drug discovery for success in clinical trials; Identify strategies for using human cells and/or tissue in every stage of preclinical research (i.e., from target identification to lead optimization and into phase 1; Identify from case studies that describe how data from human cells/tissues can be more predictive than in vivo animal studies.

Chair

Christopher Mathes, PhD, MBA

Speaker

Industry Perspective
Andre Ghetti, PhD

PMDA Update
Satoshi Tsunoda

Translation of Safety Pharmacology Testing to Human Trials: What Do We Know?
Hugo M Vargas, PhD



Speakers
avatar for Andre Ghetti

Andre Ghetti

Chief Executive Officer, AnaBios
Andre Ghetti, PhD, is our Chief Executive Officer. During the last several years, Dr. Ghetti focused on the creation of new tools and strategies to advance biomedical sciences, with special emphasis on enabling the direct study of human biology and pharmacology to accelerate the rate... Read More →
avatar for Christopher Mathes

Christopher Mathes

Chief Commercial Officer, AnaBios
As Chief Commercial Officer (CCO) of AnaBios, Dr. Chris Mathes provides leadership in business development & contributes to strategic direction. Previously, Mathes acted as CCO of Icagen. led the North American business development team for Discovery Services at Charles River & was... Read More →
avatar for Satoshi Tsunoda

Satoshi Tsunoda

Deputy Specialist, Office of New Drug IV, Pharmaceuticals and Medical Devices Agency (PMDA)
avatar for Hugo Vargas

Hugo Vargas

Executive Director, Amgen Inc.
I am an Executive Director at Amgen, and lead the Safety Pharmacology & Animal Research Center (SPARC) department. My team includes 60+ staff (Thousand Oaks, San Francisco, Burnaby BC) and we contribute actively and extensively to the entire drug discovery and development pipeline... Read More →


Wednesday June 26, 2019 4:15pm - 5:30pm
Room 2 San Diego Convention Center 111 W Harbor Drive, San Diego, CA 92101 USA